Agenus’ Post

From Jan 1, 2000, to Oct 31, 2022, FDA granted 573 oncology indication approvals for 206 distinct oncology products. Read more from a review by FDA authors: Trends in the approval of cancer therapies by the FDA in the twenty-first century. https://lnkd.in/gChVBWGe #oncology #fda #drugapprovals

The future of Cancer Management is #Targeted_Biologics. With 19% FDA approvals #Immune_Checkpoint_Inhibitors are in 2nd position after TKIs (31% FDA Approvals) according to the number of approvals.

Exciting trends in Cancer therapies "Kinase inhibitors are the dominant product class-by-number of approved products and indications, yet immune checkpoint inhibitors have the second most approvals despite not entering the market until 2011." The future is here. If your organization is looking for a consultant in Data Management or a Consultant to help you meet Audit readiness, regulatory Compliance, Quality etc..Start a conversation [email protected] and check out our website https://lnkd.in/gycKjqEZ #audit #pharmaceutical # #quality #compliance #datamanagement #consultants #medicaldevices #pharma #future #help

Approval does not equal reimbursement however, it is a vital step before a vital informed decision.

The list of references and accompanying pdfs is a huge value in addition to the work these approvals bring.

A great infographic of the progress we’ve made in oncology in only a decade. I’m looking forward to seeing how we further streamline global oncology approvals — and the next generation of treatments coming this decade. #bioeconomy #pharmaceutical #cancerresearch #oncologyresearch

𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮 𝗽𝗶𝗰𝗸𝘀 𝘂𝗽 𝗮 𝗳𝗿𝗶𝗲𝗻𝗱 𝗳𝗼𝗿 𝗧𝗮𝗴𝗿𝗶𝘀𝘀𝗼 𝗶𝗻 $𝟰𝟬𝗠 𝘂𝗽𝗳𝗿𝗼𝗻𝘁 𝗱𝗲𝗮𝗹 AstraZeneca is tossing a little cash towards Allorion Therapeutics to pick up a friend for approved lung cancer med Tagrisso. The deal includes upfront and near-term milestones of $40 million, with development and commercial milestones of $500 million total possible, plus royalties, according to a Tuesday press release. Small molecule biotech Allorion will pass a novel EGFR L858R allosteric inhibitor over to the Big Pharma to develop and commercialize globally in advanced EGFR-mutant non-small cell lung cancer (NSCLC). The program will fit in nicely with AstraZeneca’s EGFR inhibitor Tagrisso, which is already approved for NSCLC after tumor resection with curative intent. While Tagrisso has been a leader in the indication for several years, questions have begun to percolate about its future, as the therapy missed analyst consensus on sales by 2% in the third quarter and declined sequentially. Fierce Biotech https://lnkd.in/dVmkbkH8

In Oncology news today: Antibody Drug Conjugate, datopotamab deruxtecan, as a potential treatment for breast cancer, from a joint collaboration between AstraZeneca and Japan's Daiichi Sankyo, meets one of two main goals, in a study focusing on tumors that grow in response to estrogen or progesterone, which account for roughly two-thirds of BC cases.  (Early) trend data showing improvement in OS... #OncologyNews #AstraZeneca #DaiichiSankyo #BreastCancer #ADC #Pharma #Healthcare https://lnkd.in/e7pwT-Sz

🙁 Did you miss American Society of Clinical Oncology (ASCO) 2023 early last month? No worries because Clarivate has just released "The Clarivate Oncology Drugs to Watch" report with all the latest from the conference, identifying 10 new cancer drugs that are showing promise in clinical trials! These drugs target a variety of different cancers, including lung cancer, breast cancer, and melanoma. Some of the most promising drugs in the report include: #Dostarlimab, a checkpoint inhibitor that is being studied for the treatment of advanced rectal cancer. Dostarlimab has shown promising results in clinical trials, with some patients experiencing complete remission of their cancer. #Lapatinib/fulvestrant, a combination therapy that is being studied for the treatment of advanced breast cancer. Lapatinib/fulvestrant has shown promising results in clinical trials, with some patients experiencing longer progression-free survival than with other treatments. #Pembrolizumab, a checkpoint inhibitor that is being studied for the treatment of melanoma. Pembrolizumab has been shown to be effective in treating melanoma, and it is also being studied for the treatment of other cancers, such as lung cancer and head and neck cancer. These are just a few of the new cancer drugs that are showing promise in clinical trials. It is still too early to say whether these drugs will be approved for use, but they are certainly worth keeping an eye on. 👀 I am really excited to see how these new drugs develop and how they can benefit patients! 👉 If you want to read the full report follow this link: https://lnkd.in/enMkxaqD #oncology #clinicaltrials #asco23 #lungcancer #breastcancer #melanoma

Pfizer's Big Bet on Cancer: New Hope for Patients #agingpopulation #cancertreatments #drugmakers #effectivecancertreatments #globalvalueofcancertreatments #marketdemands #oncologydrugs #pfizer #Pfizerscommitmenttooncology #Pfizersdecisiontoinvestincancertreatments #pharmaceuticalindustry #researchanddevelopment #unmetneedincancertreatments